摘要
目的探讨原因不明性复发性流产患者接受主动免疫治疗的效果及接受主动免疫治疗后患者外周血CD4+CD25+调节性T细胞的变化。方法对118例原因不明性复发性流产患者进行丈夫或第三个体的淋巴细胞主动免疫治疗。在118例中随机选取26例用流式细胞术检测主动免疫治疗前后外周血CD4+CD25+调节性T细胞的变化。结果118例患者中,62例再次妊娠,56例仍在治疗中。再次妊娠的患者中6例再次发生早期流产(其中2例患者胚胎绒毛染色体发现异常),22例已成功分娩,34例仍在继续妊娠中(孕周>12周)。治疗的成功率达90.32%。随机选取的26例患者主动免疫治疗后的CD4+CD25+调节性T细胞及CD4+CD25highT淋巴细胞的表达均高于主动免疫治疗前(P<0.05)。结论主动免疫是一种治疗原因不明性复发性流产安全、有效的方法。主动免疫治疗可能通过提高外周血CD4+CD25+调节性T细胞及CD4+CD25highT淋巴细胞的表达来调控母胎界面免疫耐受的形成。
Objective To investigate the efficacy of immunothreapy in women with unexplained recurrent spontaneous abortions （URSA） and the change of CD4^＋ CD25^＋ T cells after immunothreapy. Methods 118 URSA women were immunized with lymphocytes. The percentage of CD4^＋ CD25^＋ T in peripheral blood of 26 cases randomly selected were measured by double - label flow cytometric analysis before and after lymphocyte therapy. Results Among 118 cases, 62 cases were pregnancy, 56 cases still under treatmen. 6 cases aborted again （2 cases Embryonic villus chromosomal abnormality）. 22 cases had delivered normal newborns, 34 cases are continuingly pregnant （gesrational age 〉 12 weeks）. The rate of successful pregnancy was 90.32%. After lymphocyte therapy, the percentage of CD4^＋ CD25^＋ T cells and CD4^＋ CD25^high T cells increased significantly （P 〈0.05）. Conclusion Immunotherapy with lymphocytes is effective in treating URSA. Allogeneic lymphocyte therapy can enhance the percentage of CD4^＋ CD25^＋ T cells in peripheral blood. CD4^＋ CD25^＋ T cell may play an important role in maintaining materno-fetal tolerance.
出处
《安徽医学》
2009年第10期1135-1137,共3页
Anhui Medical Journal
基金
2009年安徽省卫生厅医学科研课题(课题编号:09c21)
